Ontology highlight
ABSTRACT: Background
Alzheimer's disease (AD) is the most common cause of dementia worldwide. Omega-3 fatty acids (n-3-PUFA) are essential to normal neural development and function. Souvenaid®, a medical supplement that contains n-3-PUFA's: eicosatetraenoic acid (EPA) and docosahexaenoic acid (DHA), has emerged as an alternative, slowing cognitive decline in AD patients. In this study, we investigated the effect of dietary supplementation with n-3-PUFA, EPA, DHA, and Souvenaid® in AD patients.Aim
This systematic review and meta-analysis aim to establish the relationship between n-3-PUFA, EPA, DHA, and Souvenaid® with cognitive effects, ventricular volume and adverse events in AD patients.Methods
A systematic search of randomized control trials (RCT), cohorts, and case-control
SUBMITTER: Calderon Martinez E
PROVIDER: S-EPMC11544444 | biostudies-literature | 2024 Sep
REPOSITORIES: biostudies-literature